Glide Technologies is an Oxford-based pharmaceutical development and device company focused on needle-free administration of solid-dose therapeutics and vaccines via its proprietary Glide SDI® needle-free injector. Its pipeline includes octreotide, teriparatide, exenatide and anthrax and influenza vaccines. The company is led by Interim CEO James Otter. Glide completed a £3.2m ($4.0m) funding round. It will use the funds to complete Phase I clinical trials of its novel solid-dose teriparatide formulation during 2017. Teriparatide is approved for the treatment of osteoporosis and has global sales of over $1.3 billion.

Total raised

$4M

Funding rounds

1

Latest round

Equity

Latest activity

Feb 2017